The DCF anchor is FY2025 free cash flow of $4.1936B, derived from operating cash flow of $4.2771B and CapEx of only $83.5M, as reported in CME’s FY2025 EDGAR filings. I use a 5-year projection period, a 6.0% WACC, and a 2.9% terminal growth rate, which together are consistent with the provided deterministic model output of $471.01 per share. Revenue growth starts near the recent +6.4% FY2025 rate, then fades toward low-single digits as the business matures. Because diluted shares were stable at 360.3M and SBC was just 1.5% of revenue, I assume minimal dilution.

On margin sustainability, CME deserves better-than-average treatment because it has a position-based competitive advantage: customer captivity, benchmark liquidity pools, and strong scale economics in clearing and exchange infrastructure. Those attributes support very high incremental margins. Still, the 2025 quarterly cadence matters. Operating margin stepped down from roughly 67.7% in Q1 to an implied 61.8% in Q4, so I do not fully annualize peak first-half profitability. Instead, I assume mild mean reversion from the reported 64.9% operating margin and 64.3% FCF margin toward the low-60s over the forecast, rather than a collapse toward generic financial-industry averages. That balance between durable franchise value and modest normalization is what keeps the DCF high, but not extreme.

The result is an equity value of $171.87B, or $471.01 per share. In my view, the model is directionally credible because CME is exceptionally capital-light and cash generative, but investors should remember that such a high fair value is highly sensitive to the unusually low discount rate embedded in the valuation stack.

The market-implied setup is striking. At the current price of $307.32, the reverse DCF indicates an implied growth rate of -2.1% and an implied terminal growth rate of 2.9%. That looks conservative relative to the FY2025 record in CME’s EDGAR-reported results: revenue grew 6.4%, net income grew 15.5%, diluted EPS grew 15.4% to $11.16, and free cash flow reached $4.1936B. Put differently, the current stock price appears to assume that FY2025 was closer to a high-water mark than a repeatable base year.

There is some logic to that skepticism. Quarterly revenue and operating margin softened through 2025, with revenue of $1.64B in Q1, $1.69B in Q2, and $1.54B in Q3, while quarterly operating margin moved from about 67.7% in Q1 to an implied 61.8% in Q4. That trend, visible across the 2025 10-Qs and annual result, supports the argument that investors should not extrapolate peak transaction or rate-sensitive economics indefinitely.

My read is that the market’s implied -2.1% growth assumption is too pessimistic for a franchise with CME’s clearing scale, benchmark contracts, and capital-light model. However, I would not call the market irrational, because the valuation gap is amplified by a very low 6.0% WACC and a beta that was floored to 0.30 from a raw regression of -0.01. So the reverse DCF says less about near-term earnings risk and more about a debate over durability plus required return. I think the current price underestimates durability, but not by as much as a naïve reading of the DCF might suggest.

CME’s 2025 profitability was outstanding on any absolute basis. Full-year revenue was $6.52B, operating income was $4.23B, net income was $4.07B, operating margin was 64.9%, and net margin was 62.5%. Net income grew +15.5% on revenue growth of +6.4%, while diluted EPS reached $11.16, up +15.4%. That spread between profit growth and revenue growth is direct evidence of operating leverage in an already highly efficient exchange model. Based on the supplied EDGAR 2025 quarterly revenue and operating income figures, margin was not linear through the year, which is the main nuance a PM should care about.

Quarterly revenue moved from $1.64B in Q1 to $1.69B in Q2, then down to $1.54B in Q3, with implied Q4 revenue of about $1.65B. Operating income followed the same pattern: $1.11B, $1.13B, $972.6M, and implied Q4 of $1.0194B. That translates into approximate quarterly operating margins of 67.7%, 66.9%, 63.2%, and 61.8%. So the annual result was superb, but the run-rate exiting 2025 was clearly less robust than the average.

• The core positive is that 2025 still delivered faster earnings growth than sales growth.
• The core caution is that margin peaked early in the year and faded sequentially.
• Peer comparison to Intercontinental Exchange and Nasdaq was requested, but competitor margin figures were not provided in the authoritative spine and are therefore .
• This analysis is grounded in the supplied 2025 SEC EDGAR annual and quarterly figures, effectively the 10-Q/10-K data set embedded in the spine.

CME’s balance sheet expanded materially in 2025, but the supplied data argues for caution in interpretation rather than an automatic negative read. Total assets rose from $137.45B at 2024 year-end to $198.42B at 2025 year-end, while total liabilities increased from $110.96B to $169.70B. Shareholders’ equity increased more modestly from $26.49B to $28.73B. On the face of the balance sheet, liabilities-to-equity of 5.91 looks high. However, for an exchange and clearinghouse model, a large share of liabilities may reflect operating mechanics rather than conventional funded leverage, and the analytical findings explicitly flag that interpretation as inferred rather than proven.

Liquidity is adequate but not loose. Current assets were $165.36B versus current liabilities of $160.30B, yielding a 1.03 current ratio. Cash and equivalents improved from $2.89B to $4.42B, which is a supportive signal. Goodwill was stable at $10.51B versus $10.49B in 2024, reducing concern that 2025 balance-sheet growth was acquisition-driven. Enterprise value of $105.79B sits below market cap of $110.21B, which is directionally consistent with a net-cash-like market view.

• Total debt: because explicit debt balances were not provided in the spine.
• Net debt: for the same reason, despite cash being known.
• Debt/EBITDA: because debt is missing, though EBITDA was $4.337B.
• Quick ratio: because receivables and inventory detail were not provided.
• Interest coverage and covenant risk: because interest expense and covenant disclosures were not included in the provided 10-K/10-Q data spine.

CME’s cash-flow profile is the strongest part of the financial story. Operating cash flow in 2025 was $4.2771B and free cash flow was $4.1936B. That equates to an FCF margin of 64.3% and an FCF yield of 3.8%. Most importantly, free cash flow slightly exceeded reported net income of $4.07B, implying approximately 103% FCF-to-net-income conversion. For a business already posting a 62.5% net margin, that level of conversion strongly supports earnings quality rather than undermining it.

Capital intensity remains exceptionally low. CapEx was only $83.5M in 2025, down from $94.0M in 2024. Against 2025 revenue of $6.52B, that implies CapEx of roughly 1.3% of revenue. This is a major structural advantage because modest reinvestment needs allow a larger share of operating earnings to become distributable cash. Working capital also improved in simple current-balance terms: current assets less current liabilities expanded from about $0.72B at 2024 year-end to about $5.06B at 2025 year-end.

• Operating cash flow exceeded net income, reinforcing low accrual risk.
• CapEx intensity is very low relative to both revenue and EBITDA.
• Cash conversion cycle is because receivables, payables, and operating cycle metrics were not provided.
• This assessment relies on the supplied EDGAR cash flow data and deterministic ratios, effectively the 10-K/10-Q financial spine.

The supplied data supports a favorable view of CME’s capital allocation capacity, but not a complete audit of capital allocation decisions. The positive side is clear: the company generated $4.1936B of free cash flow in 2025 on only $83.5M of CapEx, while diluted shares were effectively stable at 360.3M at 2025 year-end. Stable share count suggests stock compensation is not materially diluting owners, which is consistent with SBC at 1.5% of revenue. Goodwill was also essentially flat at $10.51B versus $10.49B in 2024, indicating 2025 did not rely on large acquisition layering to manufacture growth.

The main limitation is disclosure depth in the spine. Dividend cash payout, buyback dollars, average repurchase price, acquisition spend, and R&D expense were not provided set, so a full judgment on distribution policy versus intrinsic value cannot be made from audited inputs alone. Still, the internal economics are compelling: with ROE of 14.2%, ROA of 2.1%, and very low capital intensity, the business has the raw ingredients for shareholder-friendly allocation if management chooses to return excess cash efficiently.

• Buyback activity and whether repurchases were above or below intrinsic value: .
• Dividend payout ratio: from the authoritative spine, although institutional survey estimates exist and are not used as factual substitutes.
• M&A track record in 2025: no material change indicated by goodwill, but deal amounts remain .
• R&D as a percent of revenue versus peers: because neither R&D nor peer data was supplied.

The provided SEC/quant spine does not include audited product-level or asset-class segment revenue, so specific contract families must remain . That said, the filings still show three verified drivers of FY2025 revenue resilience. First, the core exchange and clearing franchise sustained a high run-rate across the year: quarterly revenue was $1.64B in Q1, $1.69B in Q2, $1.54B in Q3, and an implied $1.65B in Q4, producing $6.52B for the full year. Even with uneven quarter-to-quarter activity, the system held annual growth at +6.4%.

Second, operating leverage amplified whatever revenue growth CME captured. Operating income reached $4.23B, and net income rose to $4.07B, up 15.5% year over year versus revenue growth of only 6.4%. That spread implies incremental revenue drops through the model at exceptional rates.

Third, low reinvestment needs preserved pricing power in cash terms. Free cash flow was $4.1936B on only $83.5M of CapEx, according to the FY2025 10-K data spine. In practical terms, CME did not need heavy capital spending to support the revenue base, which is a critical driver of long-duration value even when detailed product mix is unavailable.

• Driver 1: Stable quarterly revenue base despite intra-year volatility.
• Driver 2: Incremental margins strong enough to convert 6.4% revenue growth into 15.5% net income growth.
• Driver 3: Asset-light model preserved nearly all economics in free cash flow.

CME’s reported unit economics are outstanding at the consolidated level even though customer-level LTV/CAC and segment ASPs are not disclosed in the provided filings. On audited FY2025 numbers, revenue was $6.52B, operating income was $4.23B, net income was $4.07B, and free cash flow was $4.1936B. That translates to a 64.9% operating margin, 62.5% net margin, and 64.3% FCF margin. Few business models sustain margins like that without either material pricing power or structural scale advantages.

The cost structure also looks unusually light. CapEx was only $83.5M in FY2025, down from $94.0M in FY2024, which means the company converts most of its earnings into distributable cash rather than having to reinvest heavily to defend the platform. Free cash flow was roughly 103.0% of net income, another strong signal that accounting profits are high quality. This interpretation is drawn from the FY2025 10-K/EDGAR data provided.

Where the evidence thins out is below the consolidated line. Per-contract pricing, customer acquisition cost, retention cohorts, lifetime value, and segment-specific expense allocations are all in this spine. The correct read, therefore, is that CME has very strong platform-level unit economics, but investors still need contract-volume and revenue-per-contract disclosures to judge whether pricing power or volume mix is doing most of the work.

• Pricing power: Inferred from 64.9% operating margin.
• Cost structure: Asset-light; CapEx only $83.5M.
• LTV/CAC: Not disclosed; customer economics must remain.

Under the Greenwald framework, CME most likely qualifies as a Position-Based moat rather than a capability-only story. The customer captivity mechanism appears to be a combination of network effects, habit formation, and switching costs. In exchange businesses, traders do not simply choose a product interface; they choose the venue where counterparties, liquidity, and clearing confidence already exist. The provided data spine cannot quantify market share, but the financial signature is consistent with this interpretation: 64.9% operating margin, 64.3% FCF margin, and only $83.5M of CapEx on $6.52B of revenue in FY2025, as reported through SEC EDGAR.

The scale advantage is the harder part of the moat. Once an exchange and clearing platform is established, incremental transaction volume should carry very high margins because the fixed technology, compliance, and risk infrastructure is already built. CME’s FY2025 results support exactly that pattern: revenue grew 6.4%, but net income grew 15.5%. That spread implies scale economics are real, not merely theoretical. If a new entrant offered the same product at the same stated price, our answer is no, it likely would not capture the same demand, because matching headline price is not the same as matching liquidity, collateral efficiency, and embedded trading behavior.

We estimate moat durability at roughly 10-15 years. The main erosion risks would be regulatory changes, structural shifts in derivatives market structure, or verified share migration to competitors such as Intercontinental Exchange or Nasdaq; however, no market-share statistics are provided here. Based on the FY2025 10-K data and deterministic ratios, the moat looks strong and durable, but not invulnerable.

• Moat type: Position-Based.
• Captivity mechanism: Network effects + switching costs + habit.
• Scale advantage: High-margin clearing/exchange infrastructure.
• Durability: 10-15 years estimated.

We start with CME’s audited 2025 revenue of $6.52B from the annual filing and treat that as the company’s current serviceable output (SOM). Because the spine does not provide contract volumes, open interest, or fee-per-contract data, the sizing model has to be framed as a market-coverage estimate rather than a strict transactional count. We therefore assume CME currently monetizes roughly 15.0% of its practical addressable pool, which implies a $43.5B TAM ($6.52B / 15.0%).

From there, we define SAM as the subset CME can realistically reach with its current product set and market access. We use 65% of TAM for SAM, or $28.3B, because not every global derivatives flow is economically or operationally addressable. On growth, we use an 8.0% CAGR for the 2025–2028 period, consistent with a mid-single- to high-single-digit expansion profile for listed derivatives activity and clearing monetization. Under that framework, TAM rises to $54.8B by 2028 and SOM rises to $8.21B if share remains flat.

The key assumption is not that CME can instantly enlarge the market; it is that the company can continue capturing a measurable slice of an already deep fee pool. That makes the sizing model useful for valuation because even a 100 bps share gain on the 2028 TAM would be worth roughly $0.55B of incremental revenue.

• SOM: $6.52B (2025 revenue)
• TAM: $43.5B inferred from assumed 15.0% share
• SAM: $28.3B inferred as 65% of TAM
• 2028 TAM: $54.8B at 8.0% CAGR

CME’s current penetration of the modeled TAM is about 15.0%, calculated as $6.52B of 2025 revenue divided by the $43.5B addressable pool. That is not a saturated reading; it suggests CME is still monetizing a minority of the practical market while maintaining a 64.9% operating margin. In other words, the company does not need to invent new demand to grow meaningfully—its job is to defend and slightly expand share in rates, equities, commodities, metals, and clearing/services.

The runway is meaningful because market growth and share capture can stack. If the addressable market compounds at 8.0% annually, TAM reaches about $54.8B by 2028. At a constant 15.0% share, CME’s implied SOM would rise to roughly $8.21B; if the company improves share by just 100 bps, SOM becomes about $8.76B. That incremental revenue matters because the model already shows strong operating leverage, and the audited 2025 revenue base is large enough that even small share gains are financially material.

Saturation risk exists, but it looks segment-specific rather than total-market-wide. The biggest near-term limiter is not demand exhaustion; it is whether CME can keep monetizing the same pool at comparable take rates as trading patterns and contract mix evolve.

• Current penetration: ~15.0% of TAM
• 2028 implied SOM (flat share): $8.21B
• 2028 implied SOM (+100 bps share): ~$8.76B
• Main saturation risk: product- and mix-level maturity, not market disappearance

CME’s core differentiation is not easily described as a single software product; it is the integration of execution venues, clearing, risk management, collateral workflows, and market-data distribution into one operating system for derivatives markets. The supplied FY2025 EDGAR data show $6.52B of revenue, $4.23B of operating income, and a 64.9% operating margin, which strongly suggests that customers are paying for embedded workflow, trust, and liquidity concentration rather than merely for commoditized transaction processing. From an investor perspective, that is an important distinction: a simple matching engine can be replicated, but an ecosystem that ties trading, clearing, and downstream data into one stack is harder to dislodge.

The filings in the supplied spine do not break out software assets, latency metrics, or uptime statistics, so those operating details are . Still, FY2025 capital intensity was extremely low, with only $83.5M of CapEx against $6.52B of revenue, indicating CME does not require heavy incremental reinvestment to preserve platform economics. The Q1-Q4 2025 revenue path of $1.64B, $1.69B, $1.54B, and roughly $1.65B also shows that technology monetization is resilient but still activity-sensitive.

• The EDGAR-derived economics imply a high-fixed-cost, low-marginal-cost platform model.
• The real proprietary layer is likely clearing integration and liquidity network effects; exact architecture detail is .
• Competitors such as Intercontinental Exchange are relevant conceptually, but direct product-by-product share comparison is in the spine.

Bottom line: CME’s stack appears proprietary where it matters most—in risk transfer workflow and post-trade integration—while the commodity pieces are likely the compute, networking, and infrastructure layers underneath. That is why the margin profile looks more like a critical financial network than a plain exchange operator.

The Data Spine does not disclose a formal R&D budget, engineering headcount, or named development roadmap, so any hard pipeline schedule must be treated as . What is verifiable is the economic capacity to fund product iteration. CME generated $4.2771B of operating cash flow and $4.1936B of free cash flow in FY2025 while spending just $83.5M on CapEx. That means management has ample room to launch adjacent data products, analytics tools, workflow enhancements, and new contract types without needing a visible step-up in capital intensity.

For a business like CME, the most valuable “R&D pipeline” is usually not a single transformative release but a steady stream of contract innovation, clearing functionality, risk-management tooling, and market-data packaging. The quarterly revenue pattern in 2025—$1.64B, $1.69B, $1.54B, then about $1.65B—suggests the current portfolio already has enough breadth to absorb activity swings. The practical implication is that future launches likely enhance monetization and retention rather than completely alter the revenue model.

• Audited product-launch timelines are in the supplied 10-K/10-Q data set.
• R&D dollars and estimated launch-by-launch revenue impact are .
• The best evidence of pipeline strength is indirect: 64.3% FCF margin and 15.5% net income growth in FY2025.

Our read is that CME’s next leg of product value will likely come from deeper monetization of market data and clearing-linked workflow, not from an entirely new platform category. If that is right, investors should watch margin durability and revenue stability more closely than headline “innovation spend.”

The supplied spine contains no patent count, no IP asset roll-forward, and no litigation schedule, so formal patent-based moat analysis is largely . That said, the financial profile points to a different kind of defensibility. A company producing $6.52B of revenue, $4.07B of net income, and a 62.5% net margin is almost certainly benefiting from intangible assets beyond code alone. In CME’s case, those likely include contract design expertise, proprietary clearing models, risk methodology, distribution relationships, and accumulated customer workflow integration. Those items may not sit neatly in a patent count, but they can still represent powerful economic IP.

The balance sheet also gives a clue. Goodwill was $10.51B at FY2025 year-end, equal to roughly 36.6% of shareholders’ equity of $28.73B. That does not prove moat quality, but it does suggest that acquired capabilities and historical consolidation have contributed meaningfully to the franchise. In addition, diluted shares remained flat at 360.3M, so per-share value creation from the platform was not diluted away.

• Patent count: .
• Estimated years of protection for key IP: .
• Trade-secret and operating-process moat: inferred from sustained 64.9% operating margin and low 1.3% CapEx intensity.

We therefore view CME’s IP moat as primarily structural and procedural rather than patent-centric. The company’s most important protected assets are likely its clearing design, liquidity concentration, regulatory embeddedness, and customer process integration—areas where competitors can imitate technology but still struggle to reproduce the full economic loop.

CME does not disclose a traditional supplier roster in the provided spine, so the relevant single point of failure is the exchange/clearing technology stack itself. Based on 2025 audited financials, the company generated $4.2771B of operating cash flow and $4.1936B of free cash flow on only $83.5M of capex, which implies the core operating chain is not dependent on a large physical procurement base. That makes vendor concentration less about raw materials and more about whether any one telecom, data-center, or software layer could interrupt trade execution or clearing.

Because no named vendors or dependency percentages are disclosed, the public-risk profile is unquantified . Even so, the operating design suggests a high dependency on continuous uptime, latency performance, and disaster recovery; if one critical node failed, the revenue impact would be indirect but immediate through lower volumes, wider spreads, or delayed clearing. I would treat the absence of supplier disclosure itself as a transparency gap, not evidence of zero concentration.

• What is known: $6.52B revenue, $83.5M capex, $4.1936B FCF in 2025.
• What is not disclosed: named vendors, single-source percentages, and contract terms.
• PM implication: the real concentration risk is hidden in uptime dependencies, not in inventory.

No regional sourcing map is provided in the spine, so any exact percentages by geography are . What can be said is that CME’s risk is likely concentrated in the geography of its connectivity and resilience stack rather than commodities or import lanes. Tariff exposure should be structurally low because the business model is service-based; geopolitical exposure would mostly arise from cross-border market access restrictions, telecom outages, or cyber incidents rather than customs duties.

On a 10-point scale, I would score geographic risk at 2/10 [INFERRED], with the caveat that this is an analytical judgment, not a disclosed company metric. The absence of inventory, freight, and warehouse exposure materially reduces the probability that geopolitics disrupts cost of goods sold the way it would for an industrial company. The key caveat is that a single-region technology failure, even if not tariff-related, could still impair clearing continuity and market access.

• Tariffs: likely immaterial in the conventional sense; no physical BOM is disclosed.
• Geopolitics: low direct exposure, but cross-border access and cyber resilience remain relevant.
• Disclosure gap: no region-by-region sourcing, redundancy topology, or disaster-recovery map is provided.

STREET SAYS: the best external proxy in the evidence base is cautious rather than outright Short. The independent institutional survey carries a 2026 EPS estimate of $11.00, below CME’s audited 2025 diluted EPS of $11.16, and a 3-5 year target range of $255.00 to $310.00. That framing implies the Street is effectively treating 2025 as close to peak earnings power, especially after quarterly revenue moved from $1.69B in Q2 2025 down to $1.54B in Q3 2025, while quarterly operating income fell from $1.13B to $972.6M. In other words, consensus appears to assume revenue growth remains modest and that incremental margins do not re-expand meaningfully from the Q3 trough.

WE SAY: the Street is anchoring too heavily on a soft quarter and not enough on CME’s full-year cash profile. We model 2026 revenue of $6.85B, up 5.1% from the audited $6.52B 2025 base, and 2026 EPS of $12.20, up 9.3% year over year. That view assumes the Q3 pause was cyclical rather than structural, with operating margin normalizing around 65.5% versus the 64.9% full-year 2025 level. Our fair value is $471.01 per share based on the deterministic DCF, with bull and bear cases of $588.76 and $376.81. Relative to the proxy Street midpoint of $282.50, our valuation is materially higher because CME combines exchange-like defensiveness with unusually high free cash flow conversion.

Bottom line: Street expectations look built for stagnation; our thesis is that audited profitability, 64.3% free cash flow margin, and a capital-light model with only $83.5M of 2025 capex support continued per-share growth. We are Long with 7/10 conviction.

There is no verified sell-side revision tape in the provided spine, so we cannot claim a precise upward or downward consensus trend by broker. That said, the available proxy data points lean flat-to-cautious. The independent survey’s 2026 EPS estimate of $11.00 sits slightly below audited 2025 diluted EPS of $11.16, which is not what a market would publish if analysts were meaningfully revising numbers upward after year-end results. Likewise, the external $255.00 to $310.00 target band places the current $307.32 stock price near the high end of the range, implying limited room for multiple expansion in prevailing Street thinking.

The operational backdrop explains that caution. CME’s 2025 quarterly pattern was uneven: revenue rose from $1.64B in Q1 to $1.69B in Q2 before dropping to $1.54B in Q3, while quarterly operating income slipped from $1.13B in Q2 to $972.6M in Q3. That likely pushed analysts to emphasize durability over acceleration. Our interpretation is that revisions are probably being held back by concern that the Q3 2025 operating margin of 63.2% could be the new normal. We disagree: the full-year audited 64.9% operating margin, $4.1936B of free cash flow, and just $83.5M of capex argue that Street numbers are more likely to drift up than down if CME avoids another Q3-style quarter.

In short, the revision setup matters because the bar appears low. With no evidence of enthusiastic upward revisions, the stock is not priced for upside surprise. For a high-quality exchange operator, that asymmetry is attractive.

DCF Model: $471 per share

Monte Carlo: $525 median (10,000 simulations, P(upside)=97%)

Reverse DCF: Market implies -2.1% growth to justify current price

On the evidence in the 2025 10-K and the Q1-Q3 2025 10-Qs, CME’s earnings quality looks strong because cash conversion is extremely tight: operating cash flow was $4.2771B and free cash flow was $4.1936B versus $4.07B of net income. That means cash from operations exceeded accounting earnings by roughly $207.1M, which is the opposite of the pattern you see when accruals are bloated or when reported profit is being inflated by working-capital timing.

The one caveat is that the spine does not provide a non-GAAP reconciliation or a discrete list of one-time items, so the exact percentage of earnings attributable to special items is . Even so, the quarterly operating profile stayed robust across the year, with operating income of $1.11B in Q1, $1.13B in Q2, and $972.6M in Q3, and the implied Q4 recovery suggests the annual result was not dependent on one-off quarter-end noise. Accrual intensity appears low, CapEx was only $83.5M for FY2025, and diluted shares stayed around 360.3M-360.4M, which reinforces the view that reported EPS was driven by underlying economics rather than financial engineering.

• Beat consistency pattern: cannot be quantified because the spine does not include consensus estimates.
• Accruals vs. cash: favorable; FCF closely tracks net income.
• One-time items: not disclosed, so the exact share of earnings is .

The spine does not include a 90-day Street estimate history, so a true revision trend cannot be measured directly. What we can observe is that the independent institutional survey’s 2025 EPS estimate of $10.50 sits below CME’s actual FY2025 EPS of $11.16 by $0.66, or about 6.3%, while the survey’s 2026 EPS estimate of $11.00 still trails the 2025 reported run-rate. That setup usually implies a favorable revision bias if analysts are updating models from published results rather than from a new negative fundamental catalyst.

In other words, the available forward markers point more toward upward EPS drift than downward cuts, but the magnitude of any 90-day revision is because the actual revision tape is missing. Revenue is the other metric most likely to be revised, but again the spine gives no near-term consensus revenue line, so any claim about breadth of revisions would be speculative. For a market-professional takeaway, the right reading is that the published 2025 10-K numbers are strong enough to force model updates, yet the supplied dataset does not let us measure how fast the sell side has responded.

• Direction: likely upward on EPS, but not directly observable.
• Metrics being revised: likely EPS and price targets; revenue revisions are .
• Magnitude: the only hard anchor is the $0.66 gap between 2025 estimate and 2025 actual EPS.

Management credibility screens well on the data available from the 2025 10-K and related 10-Q bridge because the reported annual result reconciles cleanly to the quarter stack: FY2025 revenue of $6.52B equals the $4.87B 9M cumulative figure plus the implied Q4 bridge, and FY2025 operating income of $4.23B also bridges coherently from the 9M cumulative total. That kind of arithmetic consistency matters because it suggests the company is not moving targets late in the year or relying on opaque year-end adjustments to explain performance.

There is also no visible sign of restatement risk in the supplied spine. Diluted shares were essentially flat at 360.3M-360.4M, goodwill moved only from $10.49B to $10.51B, and year-end cash improved to $4.42B. The balance sheet expanded significantly, but the sequence looks operational rather than cosmetic. On balance I would rate credibility as High, with the caveat that we do not have management guidance ranges in the spine, so we cannot formally judge forecast accuracy or whether targets were raised or cut across the year.

• Consistency: strong quarter-to-quarter reconciliation.
• Goal-post moving: no evidence.
• Restatements: none identified in the spine.

For the next reported quarter, our base case is revenue around $1.66B and diluted EPS around $2.65, assuming CME stays near the FY2025 quarterly run-rate and does not repeat the Q3 softness that took revenue to $1.54B. That estimate is a run-rate forecast, not Street consensus, because the spine does not include next-quarter sell-side numbers. The most important datapoint will be whether revenue holds above the $1.60B zone while operating income stays near or above the $1.0B mark.

If the company prints materially below those thresholds, it would signal that the mid-year slowdown was not fully temporary. If revenue instead re-accelerates toward the implied Q4 2025 level of $1.65B, the market should be more willing to re-rate the stock toward the valuation implied by the $471.01 DCF base case. The key operating watch item is simple: revenue stability matters more than a tiny EPS beat because CME already has a very high margin structure, so a revenue miss tends to hit sentiment harder than a small change in per-share earnings.

• Consensus expectations: in the supplied spine.
• Our estimate: $1.66B revenue and $2.65 EPS.
• Most important datapoint: revenue staying above $1.60B.

CME is not a consumer app story, so the alternative-data lens has to be different from what you would use for an ecommerce or software company. The most relevant proxy set would be hiring intensity in clearing technology, market-data engineering, compliance, and regulatory functions; web traffic to product pages and investor-relations pages; app-download activity for any trading or data tools; and patent filings around matching, risk management, or clearing automation. None of those verified series are supplied in the spine, so any specific directional claim would be .

That absence matters because it changes how we read the signal stack. The audited 2025 10-K shows a mature franchise with 6.4% revenue growth, 64.9% operating margin, and 64.3% free cash flow margin, but alternative data would be the best way to tell whether there is a new product or platform investment cycle starting before it shows up in revenue. For now, the correct conclusion is not that alt data is negative; it is that there is no auditable alt-data confirmation available in this pane. I would want a sustained rise in specialist job postings and patent activity before treating alternative data as a positive incremental signal.

Institutional sentiment is supportive, but not euphoric. The independent survey assigns CME a Safety Rank of 1, Financial Strength of A+, Price Stability of 100, and Earnings Predictability of 75, which is exactly what you would expect for a durable exchange franchise with audited 2025 economics of $4.23B of operating income and $4.1936B of free cash flow. That profile generally attracts long-term capital that wants steadiness rather than fast-turn trade ideas.

The problem is sponsorship, not quality. The same survey also shows Timeliness Rank 3, Technical Rank 5, and Industry Rank 73 of 94, which argues that momentum and relative-strength buyers are not crowding into the name right now. We do not have a verified social-media sentiment feed or a live hedge-fund positioning dataset in the spine, so any claim about retail excitement would be . The practical read is that institutions may be comfortable owning CME as a core quality holding, but current sentiment does not yet support an aggressive near-term rerating.

CME scores well on a Buffett-style framework because the business is both simple in concept and unusually strong in economics. Based on the FY2025 10-K data in the spine, I score Understandable Business 5/5, Favorable Long-Term Prospects 5/5, Able and Trustworthy Management 4/5, and Sensible Price 3/5, for a total of 17/20. The business model is understandable: CME converts $6.52B of revenue into $4.23B of operating income and $4.07B of net income, with only $83.5M of capex. That level of earnings density is exactly what Buffett favors—high returns on an asset-light platform that does not require heavy reinvestment to keep the franchise intact.

The long-term prospects also appear favorable because the audited numbers imply real pricing power and network effects, even if peer comparison against Intercontinental Exchange and Nasdaq is in this pane due to missing peer data. CME posted a 64.9% operating margin, 62.5% net margin, and 64.3% FCF margin in 2025, while free cash flow reached $4.19B. Management earns a 4/5 rather than 5/5 because balance-sheet optics are complex: total liabilities rose to $169.70B and current ratio is only 1.03, which requires trust in the clearing-house structure rather than a conventional industrial balance sheet. Price is the weakest Buffett category. At 27.5x earnings and 24.4x EV/EBITDA, CME is not cheap in absolute terms, but it is sensible relative to a DCF fair value of $471.01 and a reverse DCF that assumes -2.1% growth.

• Moat evidence: 64.9% operating margin and 64.3% FCF margin imply strong franchise economics.
• Capital efficiency: Capex was just $83.5M on $6.52B revenue.
• Governance comfort: diluted shares were stable at 360.3M at 2025 year-end.
• Valuation caveat: premium multiple means this is quality-at-a-price, not a classic cigar butt.

My conviction score is 8.0/10, which is high enough for a meaningful Long but not high enough for a maximum-sized position. I break it into four weighted pillars. Franchise quality: 9/10 with 35% weight, contributing 3.15 points, because CME generated $4.19B of free cash flow on $6.52B of revenue with just $83.5M of capex; evidence quality here is High because it comes from the FY2025 10-K and computed ratios. Valuation gap: 8/10 with 30% weight, contributing 2.40 points, because DCF fair value is $471.01, the Monte Carlo median is $524.86, and even the 5th percentile is $328.29 versus a stock price of $307.32; evidence quality is High.

The other two pillars temper the score. Earnings durability and balance-sheet interpretation: 7/10 with 20% weight, contributing 1.40 points, because the business is clearly cash-rich but the liability structure is complex, with $169.70B of total liabilities and a 1.03 current ratio. Evidence quality is Medium because revenue mix and debt detail are missing. Market setup and variant perception: 7/10 with 15% weight, contributing 1.05 points, because the reverse DCF implies -2.1% growth against actual 2025 revenue growth of +6.4% and net income growth of +15.5%; evidence quality is High on the numbers but Medium on the interpretation. Summing those contributions yields 8.0/10. The contrarian bear case remains valid: if 2025 proves peak earnings, the market may be correctly refusing to pay for the DCF outcome.

• Position: Long
• Target price: $476.90 probability-weighted
• Base fair value: $471.01
• Bull/Base/Bear: $588.76 / $471.01 / $376.81

The strongest historical analogy for CME is a financial infrastructure platform that behaves like a toll road rather than a classic transaction-sensitive intermediary. In 2025, CME generated $6.52B of revenue and $4.23B of operating income, implying a 64.9% operating margin. Net income reached $4.07B, up from $3.53B in 2024 and $3.23B in 2023, while diluted EPS was $11.16 with +15.4% year-over-year growth. Those figures point to a business model where incremental activity converts efficiently into earnings. CapEx was only $83.5M in 2025, versus $4.28B of operating cash flow and $4.19B of free cash flow, reinforcing the idea that CME does not need to reinvest heavily to defend or extend its platform economics.

Historically, companies with this pattern often re-rate less on raw top-line acceleration and more on resilience, predictability, and cash conversion. CME’s institutional cross-checks support that frame: Safety Rank 1, Financial Strength A+, Earnings Predictability 75, and Price Stability 100. Even on the balance sheet, equity rose from $26.49B at 2024 year-end to $28.73B at 2025 year-end. Current assets were $165.36B against current liabilities of $160.30B, for a current ratio of 1.03. That is not a “cash-rich hypergrowth” profile; it is an infrastructure profile where scale, clearing relationships, and embedded market position matter more than expansionary capital deployment.

Peer names such as Intercontinental Exchange, Nasdaq, Cboe Global Markets, and London Stock Exchange Group are relevant comparison points for framing the category, but any direct quantitative peer comparison is here because no peer financial data is provided in the spine. The useful historical lesson is narrower: when an exchange franchise sustains margins above 60%, free-cash-flow margins above 60%, and earnings growth above revenue growth, the market often eventually treats it as a scarce asset. The analytical debate for CME is whether that scarcity has already been fully capitalized at a $110.21B market cap, or whether the current price still understates the durability implied by its audited 2023–2025 earnings progression.

A second historical lens is to view CME not as a conventional cyclical company but as a business that monetizes market activity, risk transfer, and hedging demand across different regimes. That distinction matters because classic cyclical analogies usually feature collapsing margins during slowdowns and sharp recoveries during booms. CME’s audited 2025 figures do not suggest that kind of fragile operating structure. Quarterly revenue remained high across the year at $1.64B in the March quarter, $1.69B in the June quarter, and $1.54B in the September quarter, while quarterly operating income remained robust at $1.11B, $1.13B, and $972.6M, respectively. Even the softer September quarter still represented very high absolute profitability.

This steadiness suggests a historical pattern more akin to a risk-management utility whose products become more relevant during uncertainty rather than a company dependent on one-directional economic expansion. The balance sheet also reflects the mechanics of a clearing-centric model: total assets rose from $137.45B at Dec. 31, 2024 to $198.42B at Dec. 31, 2025, while total liabilities rose from $110.96B to $169.70B. Those very large balance-sheet figures can look alarming in isolation, but the analogy should not be to an industrial firm carrying heavy operating debt. Instead, the more useful read-through is that CME is a large-scale market infrastructure entity with substantial current assets of $165.36B and current liabilities of $160.30B at year-end 2025, producing a current ratio of 1.03.

Peer references such as Intercontinental Exchange, Nasdaq, Cboe, Deutsche Boerse, and Hong Kong Exchanges are in quantitative terms here, but they are useful category anchors conceptually. The historical takeaway is that exchange businesses often perform differently from the broader financial sector because they are tied to volumes, hedging needs, and volatility rather than pure credit creation. CME’s +15.5% net income growth in 2025, combined with a beta of 0.70 from the institutional survey and a Vasicek-adjusted beta of 0.30 in the WACC framework, reinforces the idea that the stock has exhibited defensive characteristics even while the business remains exposed to trading activity and market structure shifts.

The market’s treatment of CME also resembles historical debates around high-quality, slower-growing compounders. On one hand, the company delivered audited 2025 net income of $4.07B, free cash flow of $4.19B, return on equity of 14.2%, and a 62.5% net margin. On the other hand, the shares already trade at valuation levels that presume durability: 27.5x earnings, 16.9x sales, 24.4x EV/EBITDA, and 3.84x price-to-book, with a market cap of $110.21B as of Mar. 22, 2026. That combination creates a classic historical setup where investors argue over whether the business deserves to be valued like a defensive infrastructure monopoly or whether its mature growth profile should cap upside.

The interesting tension is that model-based valuation outputs are much more constructive than the headline multiples. The deterministic DCF gives a per-share fair value of $471.01, with bear, base, and bull cases of $376.81, $471.01, and $588.76. The Monte Carlo distribution shows a median of $524.86 and a mean of $530.01, with 97.2% implied upside probability versus the live price of $307.32. At the same time, market calibration implies the stock price embeds a -2.1% growth rate and a 2.9% terminal growth assumption. Historically, stocks with this pattern often become compelling when market expectations become too conservative about the longevity of cash generation rather than when reported numbers appear superficially cheap.

That is why the analogy is not to a turnaround or a cyclical re-opening stock. It is closer to a premium-quality franchise whose valuation compresses when investors fear normalization, only to recover if earnings continue stepping higher. CME’s audited results from 2023 to 2025 support that possibility: net income rose from $3.23B to $3.53B to $4.07B, while shareholders’ equity increased to $28.73B. Competitors including Intercontinental Exchange, Nasdaq, and Cboe are as valuation comparators in this dataset, but conceptually they frame the right question: should a highly cash-generative market utility with modest CapEx and rising EPS be valued like a premium compounder or a mature exchange with limited upside?

Another recurring error in historical analog work is to treat CME’s balance sheet as if it should be read like an industrial or commercial bank balance sheet without context. The audited figures are undeniably large: total assets increased from $137.45B at Dec. 31, 2024 to $198.42B at Dec. 31, 2025, while total liabilities increased from $110.96B to $169.70B. Current assets rose from $103.03B to $165.36B over the same period, and current liabilities rose from $102.31B to $160.30B. A surface reading might focus on the deterministic total-liabilities-to-equity ratio of 5.91 and conclude leverage is the core story. But the more appropriate historical analogy is a central market utility whose scale, collateral flows, and clearing role naturally create large current asset and liability balances.

What matters more for long-run equity analysis is whether the franchise is maintaining profitability, liquidity, and book value through those flows. On that score, the evidence is constructive. Shareholders’ equity increased from $26.49B to $28.73B during 2025. Cash and equivalents improved from $2.89B at year-end 2024 to $4.42B at year-end 2025. Goodwill remained stable at about $10.5B, specifically $10.49B at Dec. 31, 2024 and $10.51B at Dec. 31, 2025, suggesting no obvious acquisition-driven balance-sheet volatility in the period shown.

That pattern resembles mature infrastructure platforms that accumulate trust and embedded role over time rather than enterprises reliant on aggressive M&A or debt-funded expansion. The historical analogy is therefore not “levered financial risk” but “systemically important marketplace with large operating balances and unusually strong earnings power.” Quantitatively, that interpretation aligns with CME’s Safety Rank 1, Financial Strength A+, and Price Stability score of 100 from the institutional survey. It does not eliminate risk, but it changes which precedents are useful: analysts should compare it to other exchange and clearing ecosystems rather than to ordinary financial intermediaries.

Proxy rights cannot be confirmed from the supplied spine. The data set does not include the DEF 14A details needed to verify whether CME has a poison pill, a classified board, dual-class shares, majority voting, proxy access, or a history of shareholder proposals. Because those items are not present, this assessment is necessarily provisional rather than definitive.

What can be said from the financial spine is that CME does not show the kind of earnings distortion or dilution pattern that often accompanies weak governance. Diluted shares were 360.3M at 2025-12-31, basic EPS was 11.18 versus diluted EPS of 11.16, and stock-based compensation was only 1.5% of revenue. On balance, that argues for an Adequate governance profile pending DEF 14A verification, not a Strong score.

• Poison pill:
• Classified board:
• Dual-class shares:
• Voting standard:
• Proxy access:
• Shareholder proposal history:

Cash conversion is the cleanest signal in the file. For 2025, CME reported revenue of 6.52B, operating income of 4.23B, net income of 4.07B, operating cash flow of 4.2771B, and free cash flow of 4.1936B. That means cash from operations and free cash flow both exceeded accounting earnings, which is exactly what you want to see in a high-quality franchise. CapEx was only 83.5M, so reinvestment needs were modest relative to the cash generated.

The balance sheet is large, but not obviously broken. Current assets were 165.36B against current liabilities of 160.30B, giving a current ratio of 1.03. Total liabilities rose to 169.70B and equity ended at 28.73B, so leverage is meaningful and deserves monitoring, but there is no sign of a liquidity crisis or a restatement event. Goodwill stayed essentially flat at 10.49B in 2024 and 10.51B in 2025, and SBC was only 1.5% of revenue.

• Auditor continuity / audit opinion:
• Revenue recognition policy detail:
• Off-balance-sheet items:
• Related-party transactions:
• Unusual items: none visible in supplied spine, but proxy and audit-disclosure fields are incomplete.